D-684-2013 Class III Terminated

Recalled by Teva Pharmaceuticals USA, Inc. — Sellersville, PA

FDA drug recall D-684-2013 was initiated by Teva Pharmaceuticals USA, Inc. on Mar 15, 2013 and is designated Class III. Reason for recall: Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing The recall status is terminated (terminated Apr 10, 2014). Affected quantity: 36,708 blister packs.

Recall details

Product Type
Drugs
Report Date
Jul 17, 2013
Initiation Date
Mar 15, 2013
Termination Date
Apr 10, 2014
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
36,708 blister packs

Product description

Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, 28 day regimen, Rx only, Barr Laboratories, Inc., Pomona, NY --- NDC 0555-9034-58

Reason for recall

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Distribution pattern

Nationwide distribution. No foreign or government accounts.

Code information

NDC 0555-9034-58, Lot numbers 33802100A, exp 3/2013; 33802266A, exp 3/2013; and 33802832A, exp 8/2013.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-684-2013
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-684-2013. Report a data issue: hello@regdatalab.com.